SETD2: an epigenetic modifier with tumor suppressor functionality

Jun Li(Sun Yat-sen University), Klaas Kok(University Medical Center Groningen)

Oncotarget

May 14, 2016

10.18632/oncotarget.9368

Cited by 167

Related Papers

Extracellular Vesicles Enriched in hsa-miR-301a-3p and hsa-miR-1293 Dynamics in Clear Cell Renal Cell Carcinoma Patients: Potential Biomarkers of Metastatic Disease

|Cancers|2020|51

High expression of calcium‐binding proteins, S100A10, S100A11 and CALM2 in anaplastic large cell lymphoma

|British Journal of Haematology|2005|48

Plasma Extracellular Vesicle-Derived TIMP-1 mRNA as a Prognostic Biomarker in Clear Cell Renal Cell Carcinoma: A Pilot Study

|International Journal of Molecular Sciences|2020|20

Microbiome changes in esophageal cancer: implications for pathogenesis and prognosis

|Cancer Biology and Medicine|2023|19

Case report: TP53 and RB1 loss may facilitate the transformation from lung adenocarcinoma to small cell lung cancer by expressing neuroendocrine markers

|Frontiers in Endocrinology|2022|14